NewsEvents

Your Yourlocation: Home > Observation on the therapeutic effect of combination of tiotropium bromide(136310-93-5) and salmeterol /propofenone propofol in the treatment of severe COPD patients

[Objective] To observe the effect of combined inhalation of tiotropium bromide(136310-93-5) and salmeterol /teicoplanin inhalation in the treatment of severe chronic obstructive pulmonary disease(COPD).

[Methods] 68 patients with severe COPD were randomly divided into treatment group and control group. On the basis of routine treatment, the control group was given inhaled salmeterol /fluticason(SFC) inhalant(50μg / 500μg (18 μg), 1 day /day, adherence to treatment and observation for 1 year, every 3 months for the San Giorgio Respiratory Questionnaire(SGRQ) survey score , 6-minute walking distance test(6MD), pulmonary function test(FEV1, FEV1% of predicted value) and detailed observation and record of acute exacerbation of hospitalization and adverse drug reactions.

[Results] The scores of SGRQ were increased at 6, 9 and 12 months after treatment, and the difference of 6MD was significant(P <0.05). The total score of SGRQ in 9 and 12 months after treatment (P <0.05). The difference of FEV1 between the two groups was significantly higher than that of the control group (P <0.05), and the difference between the two groups was significantly higher than that of the control group(P <0.05) ), but there was no significant difference between the two groups (P> 0.05). There was no significant side effect in the treatment group (P <0.05).

[Conclusion] Combined with tiotropium bromide(136310-93-5) and salmeterol /propofolone propionate in the treatment of severe COPD is more effective than inhalation of salmeterol /propofenone propionate alone. It is safe and worthy of clinical application.

Address: TEL:0531-82375879 Tiotropium Bromide
© Copyright(C)2014 JINAN DEXINJIA BIO & TECH CO., LTD All Rights Reserved